---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012793"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:39:50.971962+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PBFT02 shows robust CSF progranulin increase; well-tolerated with enhanced immunosuppression

## Summary
- CSF PGRN up to 6-fold at month 1 (10.7-17.3 ng/mL) and up to 10-fold at month 6 (21.7-27.3 ng/mL), exceeding healthy controls (3.3-8.2 ng/mL).
- No serious adverse events in patients 2-5 with enhanced immunosuppression; first patient had SAEs with lower steroid regimen.
- CSF PGRN remained elevated at 12 months (34.2 ng/mL), with rate of increase slowing from 58% to 26% between months 1-6 and 6-12.
- Cohort 2 currently enrolling; Cohort 4 anticipated to open in first half of 2025 for FTD-C9orf72.
- Plasma PGRN expression remained below healthy reference levels across all five patients.

## SEC filing metadata
- accession: 0001558370-24-012793
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/0001558370-24-012793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/pasg-20240916x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012793
- JSON: https://secwatch.observer/filing/0001558370-24-012793.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.